|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX11 has also recently emerged as a tumor marker for MCL, particularly in cyclin D1-negative MCLs and to distinguish between MCLs and other cyclin D1-positive lymphomas.
|
31714947 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The methylation level of the SOX11 locus was correlated with clinicopathologic factors in primary endometrial tumors and in TCGA endometrial cohort.
|
30935961 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nevertheless, in a limited number of malignancies, SOX11 has also been identified to function as a tumor suppressor.
|
31210798 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, our study identifies SOX11 as a potential tumor suppressor in HCC and may hopefully be beneficial for the clinical diagnosis or treatment of HCC.
|
30517979 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma.
|
31173643 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, SOX11 expression in other tumour types has not yet been extensively studied.
|
30221780 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX11 is a relevant element in the pathogenesis of MCL and has been instrumental to identify two distinct clinicobiological subtypes of this tumor.
|
29738333 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX11 augments BCR signaling to drive MCL-like tumor development.
|
29615403 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Variables found to be significantly associated with a poor survival were tumor size >5 cm (p < 0.001), bcl-2 score > 40 (p = 0.034), cyclin D1 score ≤ 70 (p = 0.004), p16 score ≤ 130 (p = 0.005), p53 score > 20 (p = 0.003), Sox11 score ≤ 40 (p < 0.001) and WT1 score ≤ 270 (p = 0.02).
|
29218546 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX11 has been recently recognized as a potential tumour suppressor that is downregulated in prostate cancer.
|
29315911 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nuclear immunoreactivity for SOX11 was detected in all SPNs and five of 31 control tumors.
|
29272888 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
|
28533307 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified potential downstream effectors of SOX11 during both microinvasive and invasive tumour growth stages, including several with established links to regulation of progenitor cell function and prenatal developmental growth.
|
28707729 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, SOX11 has been reported to be often negative in MCLs clinically resembling marginal zone lymphoma and recently defined as "leukemic non-nodal" MCL in the incoming revision of the WHO classification of lymphoid tumors, for which the bone marrow biopsy is commonly the first diagnostic approach.
|
27720733 |
2017 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Promoter methylation of tumor suppressor gene SOX11 has been reported to contribute to the diagnosis and prognosis of various cancerous diseases, including gastric cancer, hematopoietic malignancies and nasopharyngeal carcinoma.
|
26925788 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of tumor suppressor gene SOX11 in prostate cancer.
|
25773392 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent studies have shown aberrant expression of SOX11 in various types of aggressive B cell neoplasms.
|
25608839 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX4 (p = 0.0002), SOX11 (p < 0.0001) and PAX6 (p = 0.0002) were significant for tumor type.
|
25804118 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, high expression of cytoplasmic and nuclear SOX11 was associated with clinicopathological factors, including earlier tumor grade, absence of lymph node metastasis and smaller tumor size.
|
25041022 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SOX11 was a potential tumor-suppressor and an independent positive prognostic factor in gastric cancer patients with less advanced clinicopathological features.
|
24604109 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IHC staining for ADAM12, FAP, and WISP1 correlated with CDR and was higher, whereas SOX11 staining was lower in tumors with earlier recurrence following excision.
|
24402778 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Presence of SOX11 protein in cutaneous malignant melanoma was related to tumour type, tumour location, lymph node metastasis and 5-year survival rate.
|
23867449 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that SOX11 contributes to tumor development by altering the terminal B-cell differentiation program of MCL and provide perspectives that may have clinical implications in the diagnosis and design of new therapeutic strategies.
|
23321250 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among them, the transcription factor, SOX11, a progenitor cell and lineage regulator of nonmammary cell types, is found highly expressed in some Brca1-/- mammary tumors.
|
23506684 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The SOX11 promoter of non-malignant cells was consistently unmethylated whereas lymphoid neoplasms with silenced SOX11 tended to acquire DNA hypermethylation.
|
21738649 |
2011 |